Researchers conducted a retrospective cohort study of 34,248 women diagnosed with locoregional breast cancer who received ...

The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive ...

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Puma Biotechnology will present clinical data on its drug neratinib in a poster presentation on April 28 at the 2025 AACR ...

BC, OCN, explained that comprehensive disease and treatment education are essential to adherence for patients with breast ...

Patients with certain subtypes of breast cancer may face a higher risk of death from the cancer if they wait more than 42 ...

Interval breast cancer rates have remained consistent over 30 years despite age-based screening, highlighting the need for ...

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo.

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.

Stein, MD, professor and co-director of the Acute Leukemia Program at City of Hope in Duarte, California, provides deeper insight into the trial design and key findings in an interview with Targeted ...